1. Pink Sheet
  2. >>Legal & IP

FTC Makes Double Reverse Payment Case Against Endo And Impax

 
• By Brenda Sandburg

The generic firm essentially paid the brand to keep its product off the market, FTC alleges in case about Opana ER litigation. Endo considered bringing back its original formulation of oxymorphone but instead reached agreement with Impax to share profits of its generic, antitrust suit claims.

WASHINGTON, DC - MAY 4: Federal Trade Commission Headquarters in downtown Washington, DC on May 4, 2015.
FTC antitrust suit targets Opana ER breach of contract settlement • Source: Shutterstock

Endo International plc’s deal with a generic rival following the market withdrawal of its Opana ER (oxymorphone extended-release) has prompted an antitrust complaint by the US Federal Trade Commission.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet